• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthThe Biden administration

Biden to distribute an additional 20 million COVID vaccines abroad

By
Josh Wingrove
Josh Wingrove
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Josh Wingrove
Josh Wingrove
and
Bloomberg
Bloomberg
Down Arrow Button Icon
May 17, 2021, 1:19 PM ET

President Joe Biden plans to send an additional 20 million doses of U.S. Coronavirus vaccines abroad by the end of June—including, for the first time, shots authorized for domestic use, where supply is beginning to outstrip demand.

Biden will announce Monday that he’ll export 20 million doses of vaccines from Pfizer, Moderna or Johnson & Johnson, on top of 60 million AstraZeneca doses he had already planned to give to other countries, according to a senior administration official familiar with the plan.

The official, who asked not to be identified ahead of planned remarks from the president, stressed that the measures are only a first step as the U.S. Pivots its attention to quelling the pandemic abroad. Biden has previously pledged that the U.S. Would soon become an “arsenal” of global vaccine supply.

Biden will also announce that he is putting Jeff Zients, who has served as the White House coronavirus response coordinator, in charge of his effort to beat back the pandemic globally, the official said. Zients will work with the National Security Council and other agencies to steer doses abroad.

White House Press Secretary Jen Psaki confirmed the announcement, saying that the doses would go “to help countries battling the pandemic,” without specifying which ones. The 60 million AstraZeneca doses are subject to a safety review before they’ll be shipped.

“We are waiting for, of course, AstraZeneca, as you know, to go through the approval process of the FDA, but this will put 80 million doses out into the world by the end of June,” Psaki said.

The announcement is a watershed moment in the pandemic and a pivot for Biden’s administration. The U.S. Government, under two presidents, claimed nearly all of the first several hundred million doses of vaccines produced on its soil. That approach allowed Biden to advance what has been one of the most successful domestic vaccination efforts in the world, but fueled inequities between nations that can produce their own shots and those that can’t.

The Pfizer, Moderna and Johnson & Johnson vaccines are authorized for use in the U.S., but AstraZeneca’s shot is not. It wasn’t immediately clear which countries would receive U.S. Shipments.

Mexico and Canada have already received doses of the U.S. AstraZeneca stockpile, and Pfizer has begun shipping doses of its U.S.-produced vaccine to countries including Mexico, Canada and Uruguay, apart from the Biden administration’s plans to share doses.

The U.S. Domestic vaccination campaign is beginning to run out of willing arms. The country is set to cross a threshold of 60% of adults who’ve received at least one shot on Monday.

In need of shots

Meanwhile, scores of low-income nations and even some developed countries are struggling to secure supplies of vaccines.

Covax, a global program aimed at easing vaccine procurement and access for lower-income countries, is facing a supply shortage and expects the shortfall to reach about 190 million doses next month, UNICEF, one of its partners, said on Monday. Biden has previously announced a pledge of up to $4 billion for Covax.

Biden has said he would only share U.S.-purchased doses once there was enough supply to meet U.S. Demand. Manufacturing errors at a Baltimore plant resulted in a contaminated batch of Johnson & Johnson’s shot and greatly slowed production of the vaccine, once envisioned as a pillar of U.S. Supply. Instead, the U.S. Has relied almost entirely on the Pfizer and Moderna shots.

Biden has faced pressure to do more to help the world, as the U.S. Winds down nearly all mitigation measures such as masking and other countries try to quell fresh outbreaks and new variants with limited vaccine supply. Biden has launched what he calls a “new phase” of his pandemic effort, turning to the painstaking work of persuading more hesitant Americans to get shots as demand dries up among people eager for vaccination.

U.S. Caseloads continue to fall, with 16,857 new cases recorded Sunday, the lowest daily total since March of 2020—though Sundays are typically the lowest daily total of any week. The pace of vaccinations has fallen by over a third from a month ago, and is hovering now at about 2 million doses a day.

Vaccine exports have been a thorny issue for Biden, who has tried to reclaim a mantle of U.S. Leadership abroad while also borrowing many of the America-first tendencies of his predecessor, Donald Trump, in his pandemic response. While the European Union and India mixed vaccine exports with domestic allocation, the U.S. Has for months cornered the market on its supply, effectively preventing early exports.

Trump and Biden used wartime powers to prioritize their orders from U.S. Plants, effectively placing the government at the front of the line. U.S. Orders also include contractual clauses limiting the government’s ability to share doses abroad.

The administration sought to skirt those restrictions by framing the 4.2 million AstraZeneca doses already shipped to Mexico and Canada as a “loan.”

—With assistance from James Paton.

Our mission to make business better is fueled by readers like you. To enjoy unlimited access to our journalism, subscribe today.
About the Authors
By Josh Wingrove
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.